

WHY THE FDA INTEREST IN PATIENT PREFERENCE?: WEIGHING RISKS AND BENEFITS OF INNOVATIVE LIMB PROSTHETICS

Leslie Wilson, Ph.D. & David Szeto, Pharm D. Student, Rahil Shaw, Fellow University of California San Francisco Departments of Pharmacy and Medicine

Leslie.Wilson@ucsf.edu 415-990-1012

PATIENT PREFERENCES: BREAKING NEW GROUND IN REGULATORY SCIENCES

- Patient groups demanding voice in regulatory and medical decisions
- □ FDA stated they will consider patient preference in drug and device benefit/risk decisions
 - FDA published a Patient Preference Information Guidance
 - CBER & CDER include patient preference information as a goal to patient-focused drug development
- Urgent need for more examples to inform decisions: Obesity, Duchenne's, MS, Retinal Disease, Renal Replacement devices, Islet cell transplant
- Must meet scientific rigor: DISCRETE CHOICE MODELS
- UCSF/Stanford CERSI center: Major role in Education and Science of Discrete Choice
- Our studies provide MODELS of technique and validity for regulatory decisions
 - Osseointegration and myolectric control in prosthetics
 - Renal Replacement Therapies
 - ☐ Islet cell transplant in T1 Diabetes

A MODEL OF VALID PATIENT PREFERENCE MEASUREMENT: LUKE SKYWALKER PROSTHETICS

- Rapid innovation in new prosthetic devices is astonishing
- □ By 2020, 2.2 million people with limb loss
- □ 70% don't use their prosthetic device


PROSTHETIC ADOPTION IS HIGHLY PREFERENCE SENSITIVE

IT IS ESSENTIAL TO KNOW HOW PATIENTS WEIGH RISKS AND BENEFITS


OF NEW PROSTHETIC DEVICES FOR REGULATORY DECISIONS

OBJECTIVE: Determine how patients weigh risks/benefits of 2 prosthetic innovations & test validity for regulatory decisions

Osseointegration



Myoelectric Control



PATIENT PREFERENCE MEASUREMENT: DISCRETE CHOICE

Attributes	Device A	Device B	Attributes	Device A	Device B
Percent who experience daily pain	2 in 10	0 in 10	Percent who experience daily pain	2 in 10	0 in 10
Independence in cooking dinner	Completely independent	Not independent at all	Independence in cooking dinner	Completely independent	Not independent at all
Number of grip patterns, providing different strengths and smoothness of motion	8 grip patterns, full strength and fluid motion	2 grip patterns, little strength and choppy motions	Number of grip patterns, providing different strengths and smoothness of motion	8 grip patterns, full strength and fluid motion	2 grip patterns, little strength and choppy motions
Chance of having a serious but treatable infection	1/100	No chance	Chance of having a serious but treatable infection	50/100	No chance
WHICH DEVICE WOULD YOU CHOOSE ?			WHICH DEVICE WOULD YOU CHOOSE ?		

Progress: Patient Preferences for Risks/ Benefits of Osseointegration Prosthetics: Patients with Upper Limb Loss

Sample

- We surveyed 25 adults with at least one ULL above the wrist.
- Recruited from: Amputee Coalition, UCSF Prosthetic Clinics, VA Medical Centers, Social media (Instagram and Reddit)
- Surveys administered by computer either in-person or online with video chat

Innovations Tested

Osseointegration Myoelectric Control

Design: Choice Based Conjoint Approach (CBC)


- Sawtooth Software: random, full profile, balanced overlap design
- 18 choice-paired questions, with opt out question post forced choice

Analysis:

 Mixed effects logistic regression calculated beta coefficients as part-worth utilities to reflect preferences.


ULL Choice Based Conjoint Measure Used Video to Show Complex Motions





CHARACTERISTICS OF PERSONS WITH UPPER LIMB LOSS (N=23)

Upper Limb Loss



RESULTS:	PREFERENCE SCORES FOR RISKS	AND
BENEFITS O	OF DEVICE (N=23)	

- Compared with inability to COOK DINNER INDEPENDENTLY, needing some help increases preference by 1.11 & complete independence by 1.70
- ❖ After 2 GRIP PATTERNS, preference for 4 GRIP PATTERNS is greater (1.37) than for 8 (1.23)
- ❖ Preference for NO SKIN PROBLEMS is 0.60, and EASY ATTACHMENT is 0.59
- ❖ Each 10% increase in CHANCE OF DAILY PAIN decreases preference by 1.47
- ❖ Each 1% increase in **TREATABLE INFECTION** decreases preference by 0.15.
- ❖ Each 1% increase in **DEVICE FAILURE FOR 5 YRS** decreases preference by 0.65
- ❖ Compared to none, 2 HOSPITAL SURGERIES decreases preference by 0.58 and 4 SURGERIES by 1.08.
- ❖ FEELING CONNECTED & SENSATION are not important.

Attribute	β - coefficient	SE	95% CI	P-value
PAIN	-1.47	0.33	-2.12 to -0.82	<0.001
DINNER: Not independent at all	Reference	-	-	-
Need some help	1.11	0.20	0.71 to 1.50	<0.001
Completely independent	1.70	0.21	1.29 to 2.11	<0.001
EASE: Heavy socket and harness	Reference	-	-	-
Easily clips onto screw in bone	0.59	0.23	0.14 to 1.05	0.01
No skin problems	0.60	0.23	0.14 to 1.06	0.01
No heavy socket and harness	0.31	0.23	-0.15 to 0.76	0.18
INFECTIONS TREATABLE	-0.15	0.04	-0.23 to -0.08	<0.001
CONNECTED: Not feel connected	Reference	-	-	-
Feels somewhat connected	0.18	0.20	-0.22 to 0.57	0.37
Feels connected like normal arm	0.33	0.20	-0.07 to 0.72	0.10
TOUCH: No sensations	Reference	-	-	-
Barely feel object	-0.33	0.20	-0.73 to 0.06	0.10
Feel object is rough or smooth	0.02	0.20	-0.38 to 0.41	0.94
FAILED DEVICE 5 YEARS	-0.65	0.50	-1.63 to 0.34	0.20
PROCEDURES: None	Reference	-	-	-
One clinic procedure	-0.15	0.23	-0.60 to 0.30	0.52
Two hospital surgeries	-0.58	0.23	-1.03 to013	0.01
Four hospital surgeries	-1.09	0.23	-1.54 to -0.63	<0.001
GRIPS: Two pattern grip	Reference	-	-	-
Four pattern grip	1.37	0.21	0.97 to 1.77	<0.001
Eight pattern grip	1.23	0.20	0.83 to 1.63	<0.001

OPRA PRO study results VS CBC PPI results: Persons w/ LLL seem to care more about risks than benefits https://www.accessdata.fda.gov/cdrh_docs/pdf8/H080004B.pdf (n=65)

BENEFITS:

Improved range of movement around the hip joint, as motic
was unimpeded by a socket brim. This was demonstrated by
increased range of motion scores from baseline to 24
months;

- ☐ Increased prosthetic use, level of function and mobility, including longer walking distances and increased sitting comfort as demonstrated by improvements in Q-TFA subscores;
- ☐ Improved quality of life as demonstrated by the Q-TFA;
- ☐ Reduced socket related soft tissue problems;

RISKS:

- ☐ Infection: 31 (61%) subjects with 44 events: o Superficial infection: 28 (55%) subjects with 40 events o Deep infection 3 (6%) subjects with 4 events
- ☐ Mechanical complication of the implant: 4 (8%) subjects wit 9 events
- ☐ Pain: 6 (12%) subjects with 6 events
- ☐ Injury: 4 (8%) subjects with 4 events.

Attribute	Odds Ratio	6-	SE	95% CI	P-value
		coefficient			
Serious infection	0.1840	-1.69	0.22	-2.12 to -1.26	<0.001
Complete failure rate	0.2253	-1.49	0.27	-2.03 to -0.95	< 0.001
Time without prosthetic					
No time without prosthetic		Reference	-	-	-
9 months	0.3718	-0.99	0.11	-1.20 to -0.77	< 0.001
4 months	0.5258	-0.64	0.11	-0.86 to -0.43	< 0.001
Activity Limitations					
No limitations		Reference	-	-	-
No impact sports	0.5230	-0.65	0.13	-0.89 to -0.40	< 0.001
No public pools	0.5757	-0.55	0.13	-0.80 to -0.31	< 0.001
No excess pivots or twists	0.6816	-0.38	0.12	-0.63 to -0.14	0.002
Avoid socket problems					
No sensations		Reference	-	-	-
Avoid socket perspiring, skin	1.2577	0.21	0.12	-0.03 to 0.46	0.09
chafing, and weight					
Rapid snap on	1.3305	0.29	0.13	0.04 to 0.53	0.02
Comfort sitting	1.3764	0.32	0.12	0.08 to 0.56	0.01
Sense of limb perception					
No sense of limb		Reference	-	-	-
Feel somewhat sense of limb	1.2322	0.21	0.11	-0.003 to 0.42	0.053
Feels connected like normal limb	1.5746	0.45	0.11	0.24 to 0.67	< 0.001
Improved motion and fatigue					
Almost normal walking gait		Reference	-	-	-
Easily maneuver leg into car or	0.9145	-0.09	0.12	-0.33 to 0.15	0.47
under a table					
Need fewer or no aides on	0.8199	-0.20	0.13	-0.44 to 0.05	0.11
uneven ground					
Daily walks longer with less	0.0160	-0.09	0.13	-0.33 to 0.16	0.49
fatigue					
Chance of daily pain	0.2145	-1.54	0.18	-1.89 to -1.19	< 0.001

FDA IMPACT: VALUE AND CHALLENGES

- PPI INFORMATION CAN:
 - □ Support FDA risk benefit decisions: Sub analysis can target risk to those that benefit most
 - ☐ Inform FDA Guidences: Define PPI study scientific quality
 - Support patient advocacy for rare diseases
 - Inform drug/device development & clinical trial outcomes
- CHALLENGES
- □ Lack of consensus on the definition and scope of PPI (scientific patient input, not just a patient survey)
- Lack of agreement on methods which meet needs of patients and FDA
- Shortage of Experts and Funding
- ☐ CERSI CENTERS PLAY MAJOR ROLE: Goals to advance regulatory science through innovative research, education, and scientific exchanges

❖U. MD,. UCSF-Stanford, Johns Hopkins U., Yale-Mayo Clinic (centers of excellence in regulatory science)